Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03219333 | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer(EV-201) | completed | Phase 2 | 219 | Astellas Pharma IncINDUSTRY | 8 | Aug 27, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 |
| clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | completed | Phase 2 | 76 | Matthew GalskyOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03319745 | Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04525131 | Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors | completed | Phase 2 | 12 | CicloMed LLCINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02108652 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | completed | Phase 2 | 310 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT02951767 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | completed | Phase 2 | 119 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03892642 | Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer(OU-SCC-ABC) | completed | Phase 1 / Phase 2 | 18 | University of OklahomaOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04073602 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 19 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | completed | Phase 1 / Phase 2 | 127 | Processa PharmaceuticalsINDUSTRY | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03809013 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 64 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03636256 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 36 | NanOlogy, LLCINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00002914 | Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract | completed | Phase 2 | 40 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT00003129 | Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | completed | Phase 2 | 75 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00005644 | Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00053209 | Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT04311580 | Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure | completed | Phase 2 | 52 | University of Rome Tor VergataOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT00004223 | Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 18, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT03472274 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)(DUTRENEO) | completed | Phase 2 | 101 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04209192 | Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) | completed | Phase 2 | 75 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT02281383 | Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03464734 | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | completed | Phase 2 | 70 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT01688999 | Cabozantinib for Advanced Urothelial Cancer | completed | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2024source: clinicaltrials